Steven Van der Plas

4PUBLICATIONS
17CO-AUTHORS
Molecular medicineCarbon capture engineering (excl. sequestration)Cheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|May 16, 2026
Pharmacological Characterization of GLPG3667, a Tyrosine Kinase 2-Selective Inhibitor, for the Treatment of Inflammatory and Autoimmune Diseases.

|Sep 14, 2021
Correction to "Discovery of GLPG2451, a Novel Once Daily Potentiator for the Treatment of Cystic Fibrosis".

Steven E Van der Plas, Hans Kelgtermans, Oscar Mammoliti

|Jan 05, 2021
Discovery of GLPG2451, a Novel Once Daily Potentiator for the Treatment of Cystic Fibrosis.

Steven E Van der Plas, Hans Kelgtermans, Oscar Mammoliti

|Nov 18, 2017
Discovery of N-(3-Carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-lH-pyrazole-5-carboxamide (GLPG1837), a Novel Potentiator Which Can Open Class III Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channels to a High Extent.

Steven E Van der Plas, Hans Kelgtermans, Tom De Munck

Pageof 1

Frequent Collaborators

1 joint publications

Oscar Mammoliti

1 joint publications

Céline Cottereaux

1 joint publications

May-Linda Lepage

1 joint publications

Isabelle Parent